Impact factor (WEB OF SCIENCE - Clarivate)

2 year: 7.2 | 5 year: 6.6


Higher cardiovascular disease risks in people living with HIV: A systematic review and meta-analysis

San Zhu1,2*, Wenjing Wang2*, Jiaze He2*, Wenshan Duan2, Xiaoran Ma3, Honglin Guan4, Yaxin Wu2, Sibo Li2, Yanbing Li5, Tian Tian5, Wenjun Kong6, Dongxia Wu2, Tong Zhang2, Xiaojie Huang2

1 West China School of Medicine, Sichuan University, Chengdu, Sichuan, PR China
2 Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, PR China
3 Tianjin University, Tianjin, PR China
4 Hematology Department, The First Affiliated Hospital of China Medical University, China Medical University, Shenyang, PR China
5 Cardiovascular Department, Beijing Youan Hospital, Capital Medical University, Beijing, PR China
6 Department of Opthalmology, Beijing Youan Hosptial, Capital Medical University, Beijing, PR China
* Joint first authorship.
† Senior authorship.

DOI: 10.7189/jogh.14.04078




The prognosis of AIDS after active antiretroviral therapy (ART) and the quality of life of people living with HIV (PLWH) are both affected by non-AIDS-related diseases such as cardiovascular disease (CVD). However, the specific risk ratios between PLWH and individuals negative for HIV are poorly understood. We aimed to systematically review and investigate the CVD risk factors associated with HIV.


We searched PubMed, Embase, Web of Science, and Cochrane Library databases between 1 January 2015, and 12 May 2023 for articles reported the prevalence and risk factors of CVD such as hypertension, dyslipidaemia, coronary artery disease (CAD), and myocardial infarction (MI). Due to the high heterogeneity, we used a random-effects model to analyse the data. All statistical analyses were performed using Stata/MP 17.0 with 95% confidence intervals (CIs).


We analysed 31 eligible studies including 312 913 PLWH. People living with HIV had higher risks of dyslipidaemia (hazard ratio (HR) = 1.53; 95% CI = 1.29, 1.82), CAD (HR = 1.37; 95% CI = 1.24, 1.51), and MI (HR = 1.47; 95% CI = 1.28, 1.68) compared to individuals without HIV. However, there were no significant differences in the prevalence of hypertension between groups (HR = 1.17; 95% CI = 0.97, 1.41). Subgroup analysis revealed that men with HIV, PLWH who smoked and the elderly PLWH had a high prevalence of CVD. Moreover, the disease prevalence patterns varied among regions. In the USA and Europe, for instance, some HRs for CVD were higher than in other regions. Active ART initiation after 2015 appears to have a lower risk of CVD (hypertension, hyperlipidaemia, CAD). All outcomes under analysis showed significant heterogeneity (I2>70%, P < 0.001), which the available study-level variables could only partially account for.


People living with HIV had a higher CVD risk than the general population; thus, CVD prevention in PLWH requires further attention. Rapid initiation of ART may reduce the incidence of CVD in PLWH. For timely screening of CVD high-risk individuals and thorough disease management to prevent CVD, further studies are required to evaluate the risk factors for CVD among PLWH, such as age, region, etc.


PROSPERO (CRD42021255508).

Print Friendly, PDF & Email

The widespread use of antiretroviral therapy (ART) has risen the life expectancy of patients with AIDS [1]. Simultaneously, the number of elderly people living with HIV (PLWH) is rising and expected to continue. The proportion of PLWH worldwide aged ≥50 years or was expected to increase from 21% at the end of 2019 to 73% by 2030, according to the latest estimates by the United Nations Programme on HIV/AIDS [2]. Thus, the prognosis and quality of life of PLWH will be impacted by AIDS and various non-AIDS-related diseases such as cardiovascular disease (CVD) [3,4]. The 2021 United States Department of Health and Human Services antiviral treatment guidelines recommended the close monitoring of cardiovascular health in elderly PLWH [5]. Recent studies have demonstrated the pooled prevalence of coronary artery disease (CAD) [6,7], cardiac dysfunction [8,9], dyslipidaemia [10], and hypertension in PLWH [11]. They have indicated that in regions with established ART, CVD is the primary cause of mortality [12]. Various studies have highlighted subclinical CAD as a marker of cardiovascular clinical events [13], further highlighting the importance of reducing the relative risk of myocardial infarction (MI) in PLWH [14,15]. However, the supposedly higher CVD risk in PLWH clinically has not been specifically and comprehensively illustrated; thus, this complication is likely underestimated in the vulnerable population [16].

In 2015, the World Health Organization recommended immediate initiation of ART for PLWH with uncertain CD4+T cell count [17]. However, clinical monitoring and treatment of CVD in PLWH have not received sufficient attention. Hence, a more comprehensive assessment of CVD burden in PLWH would aid in identifying the specific needs for reducing CVD risk factors.

The present systematic review and meta-analysis assessed the pooled effect size (ES) for specific CVD risk in PLWH compared with that in normal individuals, according to different factors. Considering the broad nature of CVD, we focused on four representative conditions: hypertension, dyslipidaemia, CAD, and MI.


The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) [18] (CRD42021255508) and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [19], which can be found in the PRISMA checklist (Online Supplementary Document).

Data sources and search strategy

For studies reporting the prevalence and risk of CVD in PLWH published between 1 January 2015, and 12 May 2023, we searched the PubMed, Embase, Web of Science, and Cochrane Library databases using following subjects and keywords: ‘coronary heart disease?’, ‘atherosclerosis’, ‘myocardial infarction’, ‘dyslipidaemia’, ‘hyperlipidaemia’, ‘hypertension’, ‘ART’, ‘HIV’, ‘hazard ratio’, ‘odds ratio’, and ‘risk ratio’. To discover new pertinent articles while writing the manuscript, automatic PubMed literature alerts were set up. We also used a back search of reference lists of eligible studies and relevant review papers to ensure the comprehensive search (Tables S1–S2 in Online Supplementary Document) provide specifics about the search strategy.

Inclusion and exclusion criteria

Inclusion criteria were studies (1) published from 2015 onward that reflected the current state of HIV treatment and disease management; (2) published in English; (3) that presented the odds ratio (OR), or hazard ratio (HR), or relative risk (RR) of PLWH and the general population or the incidence of MI, CAD, hypertension, or dyslipidaemia; (4) that stratified the results by region, age, follow-up duration, CD4+T cell count, plasma viral load, and ART use; and (5) that used standardised definitions for the diseases presented in Table S3–S4 in Online Supplementary Document.

To minimise the consequences of selective reporting, unpublished reports and conference abstracts were eliminated. Furthermore, studies using intermediate, surrogate, or CVD biomarker outcomes as well as those involving animals, children, or pregnant women were excluded. Studies examining no systemic hypertension (such as pulmonary and portal hypertension) or those recruiting patients with conditions linked to hypertension (such as kidney failure and heart disease) were omitted. Table S5 in Online Supplementary Document details these criteria.

Data sources and search strategy

We screened and managed literature with EndNote X9. Three reviewers (S Zhu, WJ Wang, and JZ He) independently reviewed the titles and abstracts to assess their eligibility. We resolved differences through discussion; when necessary, we invited a fourth investigator (WS Duan) to help reach a consensus.

We gathered all data on the prevalence and risk factors for hypertension, dyslipidaemia, CAD, and MI among PLWH. We also developed a standardised table to extract data such as authors, study year, sample size, study demographic characteristics, and outcome measures. A third investigator (S Zhu) compiled the results after two reviewers (WJ Wang and JZ He) independently extracted the data.

Study selection and data extraction

We screened and managed literature with EndNote X9. Three reviewers (S Zhu, WJ Wang, and JZ He) independently reviewed the titles and abstracts to assess their eligibility. We resolved differences through discussion; when necessary, we invited a fourth investigator (WS Duan) to help reach a consensus.

We gathered all data on the prevalence and risk factors for hypertension, dyslipidaemia, CAD, and MI among PLWH. We also developed a standardised table to extract data such as authors, study year, sample size, study demographic characteristics, and outcome measures. A third investigator (S Zhu) compiled the results after two reviewers (WJ Wang and JZ He) independently extracted the data.

Risk of bias analysis

The Newcastle-Ottawa Scale was used to evaluate cross-sectional and cohort studies [20]. Overall, scores of 7–9, 6, and 0–5 were considered high, medium, and low quality, respectively. A third researcher (S Zhu) resolved conflicts after two researchers (WJ Wang and SB Li) independently screened and extracted the data. Table S6 in Online Supplementary Document shows the results of the quality evaluation.

Statistical analysis

The statistical analyses and 95% confidence intervals (CIs) were produced using Stata/MP 17.0 (StataCorp, College Station, TX, USA). We pooled the prevalence of various CVDs (hypertension, dyslipidaemia, CAD, and MI). The risk of CVD (HR) in PLWH compared with HIV-uninfected people was summarised and presented. In the search, we included ‘HR’, ‘RR’ and ‘OR’ for the purpose of including relevant studies as comprehensively as possible. In general, the OR and the RR cannot be substituted for each other. However, the disease (outcome) studied is relatively rare, and when its occurrence rate is less than 10%, OR can be used as an approximate estimate of RR [21]. For the conversion of RR, HR and OR, we used OR = ((1-P0)*RR)/(1-P0*RR) and RR ≈ (1-eHR*ln(1-P0))/P0 in the data analysis. P0 refers to the incidence of the control groups [22].

Using I2 statistic, heterogeneity between studies was analysed. I2 values of 0–40%, 30–60%, 50–90%, and 75–100% indicated low, medium, substantial, and high heterogeneity. A fixed- or random-effects model was utilised for data synthesis, depending on the heterogeneity. To investigate the origins of heterogeneity, subgroup analyses were conducted to explore factors affecting the risk of CVD. Analyses were stratified by age (≤50 or >50 years), region, race, follow-up duration, and proportions of males and smokers. Additionally, correlations were examined between important HIV-related indicators (time since HIV diagnosis, ART duration, and CD4+T cell count) and the HR of CVD to assess the impact of immune factors on CVD risk. We pooled the data using adjusted risk estimates to minimise bias.

We used funnel plots to assess publication bias and also performed the sensitivity analysis by excluding studies from the meta-analysis one by one. The threshold for statistical significance was set at P < 0.05.


Study characteristics and quality assessment

The comprehensive database search identified 5581 records. After assessing titles and abstracts and removing duplicates, 499 articles were left for full-text evaluation. During the full-text screening, 114 articles reporting none the four chosen CVD were excluded, 306 articles were excluded because the subjects did not match the inclusion criteria, and 48 articles were excluded because the required data could not be obtained. Finally, a total of 31 studies [2353] meeting the inclusion criteria were included, of which 17 were cross-sectional [23,25,32,36,43,4553] and 14 were prospective cohort studies [24,2631,3335,3742,44] (Figure 1).

Figure 1.  Flowchart of the inclusion of studies.

These studies involved 40 551 855 participants, 312 913 of whom were PLWH. Over 80% of patients were men. The majority of these studies were carried out in North America and Europe. The detailed baseline characteristics of the trials and enrolled individuals were listed in Table 1.

Table 1.  Characteristics of the included studies

ART – antiretroviral therapy, CAD – coronary artery disease, IQR – interquartile range, MI – myocardial infarction, NR – not reported, SD – standard deviation

*The proportion of indicators in people living with HIV.

†CD4 nadir means the lowest point to which CD4 counts have fallen during the course of the study.

Two medium-quality studies and 29 low-quality studies were detected in the risk of bias analysis, indicating good quality (Table S6 in the Online Supplementary Document). The funnel plots did not reveal statistically significant indication of publication bias (Figure S1 in the Online Supplementary Document).


The hypertension analysis included 17 studies [2339] involving 39 562 734 patients. Figure 2 showed that the prevalence of hypertension in PLWH was 32%. Comparable to general population, the HR of PLWH having hypertension was 1.17 (95% CI = 0.97, 1.41, I2 = 98%) (Figure 3). Subgroup analysis revealed a slightly increased in hypertension risk with age (≥50: HR = 1.36, 95% CI = 0.97, 1.91; <50: HR = 1.08, 95% CI = 0.88, 1.31) (Figure S2 in the Online Supplementary Document). North America had higher risk in hypertension (HR = 1.40; 95% CI = 1.02, 1.92) compared with other regions (Europe, Africa, and Asia) (Figure S3 in the Online Supplementary Document). The HR was 1.08 (95% CI = 0.94, 1.25) after 2015 compared with 1.36 (95% CI = 0.85, 2.18) before 2015, based on the follow-up duration (Figure S4 in the Online Supplementary Document). The proportions of men and smokers did not differ significantly (Figures S5–6 in the Online Supplementary Document). The racial-ethnic differences also did not affect the risk of hypertension (Figure S7 in the Online Supplementary Document). No correlation was observed between the HR of hypertension in PLWH and time since HIV diagnosis, ART duration and CD4+T cell count (Figure S8 in the Online Supplementary Document).

Figure 2.  Forest plots of the different prevalence levels of CAD, MI, dyslipidaemia, and hypertension in PLWH. CAD – coronary artery disease, CI – confidence interval, MI – myocardial infarction, PLWH – people living with HIV

Figure 3.  Pooled HRs of hypertension, dyslipidaemia, CAD, and MI in PLWH compared to the general population. CAD – coronary artery disease, CI – confidence interval, HR – hazard ratio, MI – myocardial infarction, PLWH – people living with HIV


There were 30 043 828 patients in 10 studies [25,2729,32,33,35,3941]. In PLWH, dyslipidaemia was seen in 53% of cases (Figure 2). Compared to the general population, HR for risk of dyslipidaemia in PLWH was 1.53 (95% CI = 1.29, 1.82, I2 = 92.7%) (Figure 3). In subgroup analysis, PLWH aged ≥50 years had an HR for the risk of dyslipidaemia of 1.58 (95% CI = 1.17, 2.14), compared to those aged <50 years, who had an HR of 1.54 (95% CI = 1.07, 2.20) (Figure S2 in the Online Supplementary Document). North America and Europe showed higher risk than Africa (HR = 2.10, 95% CI = 1.67, 2.20; HR = 1.34, 95% CI = 1.08, 1.67) (Figure S3 in the Online Supplementary Document). According to follow-up duration, the group after 2015 (HR = 1.51, 95% CI = 1.13, 2.02) showed a greater risk of dyslipidaemia in PLWH (Figure S4 in the Online Supplementary Document). Meanwhile, subgroups with a larger proportion of men (>50%) or smokers (≥50%) showed more significant risk of dyslipidaemia (HR = 1.69, 95% CI = 1.41, 2.03; HR = 1.53, 95% CI = 1.15, 2.03) (Figures S5–6 in the Online Supplementary Document). We did not observe the correlation between the HR of PLWH having dyslipidaemia and HIV diagnosis and ART duration. While the HR of PLWH having dyslipidaemia showed a significant positive correlation with CD4+T cell count (Figure S9 in the Online Supplementary Document).


The CAD analysis included seven studies involving 9 798 698 patients [28,31,4246]. The risk of developing CAD was greater in PLWH (HR = 1.37; 95% CI = 1.24, 1.51, I2 = 53.5%) (Figure 3), and the prevalence of CAD among PLWH was 24% (Figure 2).

The risk of CAD was decreased among the elderly, but there was no discernible difference between groups (≥50 years: HR = 1.28, 95% CI = 1.20, 1.37; <50 years: HR = 1.50, 95% CI = 1.39, 1.62) (Figure S2 in the Online Supplementary Document). In comparison to the European group, the North American group displayed a more substantial risk (HR = 1.37; 95% CI = 1.23, 1.53) (Figure S3 in the Online Supplementary Document). The risk of developing CAD was lower in the group that was monitored after 2015 (HR = 1.38; 95% CI = 1.23, 1.55) (Figure S4 in Online Supplementary Document). The incidence of CAD did not differ between various proportions of smokers (Figure S6 in Online Supplementary Document). And the racial-ethnic differences did not affect the risk of CAD (Figure S7 in Online Supplementary Document). No correlation was observed between the HR of hypertension in PLWH and ART duration and CD4+T cell count (Figure S10 in Online Supplementary Document).


We included 10 studies involving 1 269 005 patients [28,4753]. MI was more common among PLWH compared to HIV-negative individuals (HR = 1.47; 95% CI = 1.28, 1.68, I2 = 76.8%) (Figure 3). The prevalence of MI of 12% was found in PLWH (Figure 2). Europe (HR = 1.81; 95% CI = 1.34, 2.44) and North America (HR = 1.35; 95% CI = 1.21, 1.50) had higher risks of MI based on regions (Figure S3 in the Online Supplementary Document). MI risk did not vary by follow-up duration (Figure S4 in the Online Supplementary Document). All included patients were aged <50 years, hence age subgroups were not analysed. Between the two groups, the proportion of smokers did not significantly differ (Figure S6 in the Online Supplementary Document).

To analyse the CVD risk of PLWH globally, we drew a global map to illustrate the disparities in disease risk between regions (Figure 4).

Figure 4.  Global distribution of the characteristics of cardiovascular disease risk in PLWH. HR – hazard ratio, PLWH – people living with HIV

Sensitivity analysis

The results were unaltered by the stepwise exclusion of single studies and pooled analysis of the remaining studies. Hence, the findings of meta-analysis were considered valid (Figure S11 in the Online Supplementary Document).


Principal findings

To the best of our knowledge, this systematic review and meta-analysis comprehensively assessed the prevalence and risk of developing CVD in PLWH. We focused on four typical CVD (hypertension, dyslipidaemia, CAD, and MI) to offer a more comprehensive basis for the clinical monitoring and treatment of CVD in PLWH. Our results were as follows: (1) PLWH had higher risks of hyperlipidaemia, CAD, and MI but not hypertension than the general population. (2) Similar to the general population, hypertension and hyperlipidaemia had a high prevalence among PLWH. (3) Elderly PLWH had a relatively higher risk of hyperlipidaemia, whereas the risk of CAD decreased with age. (4) We observed significant regional differences in the risk of CVD, with North America having the highest CVD risk among PLWH when compared to other countries or regions. (5) The relative risk of CVD decreased with ART initiation after 2015 (i.e. rapid ART, ART advancement). (6) The prevalence of dyslipidaemia was correlated with CD4+T cell count.

Similar to evidence from other studies [54], our meta-analysis showed that PLWH had a greater chance of developing dyslipidaemia than the general population. A previous study reported that ART was linked to modest weight gain and elevated total cholesterol and triglyceride levels [55]. However, the mechanisms underlying dyslipidaemia in PLWH remain unclear. Additionally, PLWH had a higher chance of developing CAD, which is similar to previous studies reporting that HIV infection raises the risk of CAD [53,56], but the Swiss HIV Cohort Study found that HIV infection reduced the risk of CAD by 0.5–0.8-fold [57]. These inconsistent results may be attributable to the different study regions and the limited sample size of the Swiss study. Thus, additional studies are required to substantiate the link between CAD risk and HIV infection. Studies showed that the risks of MI or stroke were 1.5–2 times greater in PLWH compared to the general population [58]. Like our findings, PLWH had a 2-fold greater risk of acute MI than the general population in a cohort without traditional CVD risk factors [59]. Surprisingly, PLWH and the general population had similar hypertension risk. Regarding the connection between HIV infection and hypertension, various studies, however, have come to conflicting results. Compared to uninfected controls, the prevalence rates of hypertension in earlier studies were lower [60], comparable [61], and higher [62] in PLWH. This may be because the general population has a stronger white-coat effect. People living with HIV may also have better health habits, regular interactions with health care workers, and are more inclined to be watched for hypertension risk factors. Consequently, further prospective researches are needed to examine the connection between HIV infection and hypertension.

Traditional risk factors linked to an elevated risk of CVD include smoking, sex, and age. Our findings demonstrated that age did not affect the relative risk of CVD in PLWH, indicating that younger patients should not be overlooked. Specifically, age enhanced the relative risk of dyslipidaemia. This may be because, with age, the cardiovascular system can undergo structural changes, arterial elasticity gradually decreases, serum cholesterol levels increase, and coronary artery disease is more likely to occur. Moreover, elderly are more sensitive to medications and experience more serious drug reactions. These changes may aggravate aging society’s personal and social medical burdens. Monitoring public health measures like screening in primary care has been shown to be help achieve the goal of ‘compression of morbidity’ [63]. However, young people are more likely to develop CAD, possibly due to relatively longer working hours and greater financial pressures. Men may have a higher risk of CVD because of social pressures, stigmatization and smoking, all of which can accelerate CVD onset and progression. Special attention to social stress and smoking status is warranted for CVD risk in PLWH.

The burden of HIV-related CVD has risen globally over the past 20 years, with major regional disparities. These disparities are most pronounced in the Asia-Pacific and sub-Saharan Africa regions [64]. Subgroup global analysis revealed that PLWH in North America had a higher CVD risk than those in other countries and regions, including Africa, whereas PLWH in Europe have a higher MI risk. Lifestyle, an underlying risk factor for CVD development, may have played an important role in these results. In North America, owing to differences in dietary habits and lifestyle, food is rich in saturated fats and high in cholesterol, coupled with life stress, sedentary behaviour, and reduced exercise. The risk of CVD was raised by these factors. Second, all diseases (including hepatitis C and depression) are expected to stimulate systemic immune activation and inflammation in women living with HIV in North America and Europe [65]. According to a worldwide study of cardiovascular risk in eight regions [66], the highest prevalence of overweight was found in Latin America, whereas hypertension and high cholesterol were common in Europe. Moreover, Latin America and Eastern Europe were notably affected by the risk factor of smoking. Combining these factors may prevent CVD associated with HIV. While there was no difference in the risk of CVD between racial groups, such as blacks and whites.

Although the literature search was conducted after 2015, some studies included patients treated with ART before 2015 and the application of ART varied widely. Older ART regimens commonly used in low-income areas (e.g. lopinavir, abacavir, and ritonavir) have side effects that compromise the cardiovascular system, including disturbances in lipid metabolism. In contrast, some regimens (e.g. dolutegravir or atazanavir) may have fewer adverse effects on the cardiovascular system [67]. Intriguingly, in the present study, the risk ratio for CVD decreased after 2015. We assume that with the improvement of ART and the promotion of ‘treatment after discovery’ policies, the side effects of ART have gradually decreased. One randomised controlled trial (RCT) reported that boosted atazanavir treatment resulted in a reduced incidence of carotid intima-media thickness progression than darunavir and ritonavir therapy [68]. In addition, the novel pathophysiological mechanisms of CVD in PLWH may involve immune reconstitution, microbial translocation, and chronic inflammation [69,70]. Inflammation and immune cell activation have also been shown to play atherogenic roles in HIV infection [71]. The promotion of ‘treatment after discovery’ can promptly suppress inflammation, effectively inhibit HIV replication, and promote immune system recovery and reconstruction, thus improving the accumulation of lipids in the body, which also supports our hypothesis.

Our analysis revealed a noteworthy observation regarding the impact of HIV infection on the immune system. Specifically, the virus leads to a reduction in CD4+T cell counts and compromises immune function. Interestingly, our findings demonstrate a strong positive correlation between dyslipidaemia and CD4+T cell counts, aligning with previous research [72]. Elevated CD4+T cell counts were linked to higher lipid levels, and naive CD4+T cells showed a positive association with peripheral blood hypercholesterolemia. This underscores the significance of immune status changes in health recovery. With the use of ART, obesity was also more common in PLWH, and CD4+T cell counts increased with normal weight and obesity [73]. These results emphasised the importance of regularly monitoring CD4+T cell counts in PLWH to potentially reduce the risk of CVD. Given the limited number of studies available, future prospective research is warranted to validate these findings.

Traditional risk factors, the direct effects of HIV infection, and the negative side effects of some antiretroviral drugs may contribute to the pathogenesis of CVD in PLWH. Non-traditional CVD risk factors including the development status of the country and an individual’s body mass index also increase the risk of CVD. Regardless of HIV infection, these risk variables increase exponentially along with the risk of CVD. The immune system is crucial for development and progression of CVD in PLWH. The bulk of research included in the current analysis were cross-sectional or cohort studies, which limits our understanding of HIV-associated CVD. Higher-level evidence such as that from RCTs is currently lacking. Therefore, additional studies are necessary to confirm these findings.


This study has several limitations. First, although CVD risk ratio was adjusted, residual confounding factors were possible. The main reasons for this lie in the higher frequency of modifiable and non-modifiable cardiovascular risks, as shown in previous studies [74]. Other confounders were equally adjusted in different studies. Second, pooled relative risk estimates were used to calculate CAD risk in PLWH, which represented the overall risk for all types of plaque in the coronary arteries but did not particularly include estimates for carotid plaque, angina, or other chronic atherosclerotic disease symptoms. Nevertheless, angina has a negligible impact on people with ischemic heart disease [75]. Therefore, this limitation had little impact on the estimated total burden. Finally, substantial heterogeneity was observed in the pooled risk ratios. Given that most data are based on global statistics, the cause of this heterogeneity is probably multifaceted and reflects variations in demography, sample size, and case ascertainment bias.


People living with HIV had a higher risk of CVD than the general population, particularly in North America and Europe. However, there were no appreciable differences in the risk of hypertension between groups. Additionally, sex, age, and tobacco use influenced the risk of CVD. As PLWH age in the post-ART era, CVD poses additional challenges for clinicians and health departments. Our estimates have important policy implications for facilitating access to health care and are now accepted recommendations for early initiation of ART. Further research is required, especially in resource-limited communities and developing countries with high rates of HIV infection, such as South Africa.

Additional material

Online Supplementary Document

[1] Funding: This systematic review was supported by a Public Health Talent Grant from the Beijing Municipal Health Commission (Global Health Governance-02-12; 2022-1-007), Capital Health Development Research (2022-2-2185; 2022-1G-3011) and “Youth” Project of Beijing Hospital Management Center (QML20211703; QML20211703).

[2] Authorship contributions: SZ and WWJ conceptualized the study. SZ, WJW and JZH conducted the literature review for all databases. SZ, WJW and SBL performed all statistical analyses. SZ, WJW, and JZH drafted the paper, with help from T Zhang, and XJ Huang. Then, T Tian, WJ Kong, and DX Wu provided useful additional input into the first draft. They also contributed to writing of the final version of the paper and checked the paper for important intellectual content. XJ Huang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

[3] Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.


[1] UNAIDS. Ending AIDS: Progress towards the 90–90–90 targets. 2017. Available: Accessed: 29 September 2023.

[2] UNAIDS. IN DANGER: UNAIDS Global AIDS Update 2022. 2022. Available: Accessed: 29 September 2023.

[3] DG Dillon, D Gurdasani, J Riha, K Ekoru, G Asiki, and BN Mayanja. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol. 2013;42:1754-71. DOI: 10.1093/ije/dyt198. [PMID:24415610]

[4] SA Fahme, GS Bloomfield, and R Peck. Hypertension in HIV-Infected Adults: Novel Pathophysiologic Mechanisms. Hypertension. 2018;72:44-55. DOI: 10.1161/HYPERTENSIONAHA.118.10893. [PMID:29776989]

[5] Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2023. Available: Accessed: 29 September 2023.

[6] F D’Ascenzo, E Cerrato, G Biondi-Zoccai, C Moretti, P Omedè, and F Sciuto. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J. 2012;33:875-80. DOI: 10.1093/eurheartj/ehr456. [PMID:22187508]

[7] F D’Ascenzo, E Cerrato, A Calcagno, W Grossomarra, F Ballocca, and P Omedè. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis. 2015;240:197-204. DOI: 10.1016/j.atherosclerosis.2015.03.019. [PMID:25797313]

[8] E Cerrato, F D’Ascenzo, G Biondi-Zoccai, A Calcagno, S Frea, and W Grosso Marra. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J. 2013;34:1432-6. DOI: 10.1093/eurheartj/ehs471. [PMID:23335603]

[9] S Erqou, BT Lodebo, A Masri, AD Ezuma, FE Ezenwankwo, and PC Okere. Cardiac Dysfunction Among People Living With HIV: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2019;7:98-108. DOI: 10.1016/j.jchf.2018.10.006. [PMID:30704613]

[10] P Patel, CE Rose, PY Collins, B Nuche-Berenguer, VV Sahasrabuddhe, and E Peprah. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. AIDS. 2018;32:Suppl 1S5-S20. DOI: 10.1097/QAD.0000000000001888. [PMID:29952786]

[11] JJ Bigna, AL Ndoadoumgue, JR Nansseu, JN Tochie, UF Nyaga, and JR Nkeck. Global burden of hypertension among people living with HIV in the era of increased life expectancy: a systematic review and meta-analysis. J Hypertens. 2020;38:1659-68. DOI: 10.1097/HJH.0000000000002446. [PMID:32371769]

[12] WK Adih, RM Selik, HI Hall, AS Babu, and R Song. Associations and Trends in Cause-Specific Rates of Death Among Persons Reported with HIV Infection, 23 U.S. Jurisdictions, Through 2011. Open AIDS J. 2016;10:144-57. DOI: 10.2174/1874613601610010144. [PMID:27708746]

[13] SM Grundy and NJ Stone. 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol: Primary Prevention. JAMA Cardiol. 2019;4:488-9. DOI: 10.1001/jamacardio.2019.0777. [PMID:30969322]

[14] MJ Feinstein, PY Hsue, LA Benjamin, GS Bloomfield, JS Currier, and MS Freiberg. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation. 2019;140:e98-e124. DOI: 10.1161/CIR.0000000000000695. [PMID:31154814]

[15] A Vachiat, K McCutcheon, N Tsabedze, D Zachariah, and P Manga. HIV and Ischemic Heart Disease. J Am Coll Cardiol. 2017;69:73-82. DOI: 10.1016/j.jacc.2016.09.979. [PMID:28057253]

[16] VA Triant, J Perez, S Regan, JM Massaro, JB Meigs, and SK Grinspoon. Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. Circulation. 2018;137:2203-14. DOI: 10.1161/CIRCULATIONAHA.117.028975. [PMID:29444987]

[17] World Health Organization. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. 2015. Available: Accessed: 29 September 2023.

[18] S Sideri, SN Papageorgiou, and T Eliades. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J Clin Epidemiol. 2018;100:103-10. DOI: 10.1016/j.jclinepi.2018.01.003. [PMID:29339215]

[19] D Moher, A Liberati, J Tetzlaff, and DG Altman. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535 DOI: 10.1136/bmj.b2535. [PMID:19622551]

[20] Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. The Ottawa Hospital Research Institute. 2023. Available: Accessed: 29 September 2023.

[21] Hulley SB, Cummings SR, Browner WS. Designing Clinical Research: An Epidemiologic Approach[J].Lippincott Williams & Wilkins, 1988.

[22] AJ Viera. Odds ratios and risk ratios: what’s the difference and why does it matter? South Med J. 2008;101:730-4. DOI: 10.1097/SMJ.0b013e31817a7ee4. [PMID:18580722]

[23] B Hasse, PE Tarr, P Marques-Vidal, G Waeber, M Preisig, and V Mooser. Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. Open Forum Infect Dis. 2015;2:ofv108. DOI: 10.1093/ofid/ofv108. [PMID:26284258]

[24] A Tripathi, JM Jerrell, TN Skelton, MA Nickels, and WA Duffus. Incidence of primary hypertension in a population based cohort of HIV-infected compared with non-HIV-infected persons and the effect of combined antiretroviral therapy. J Am Soc Hypertens. 2015;9:351-7. DOI: 10.1016/j.jash.2015.01.007. [PMID:25766497]

[25] EE Friedman and WA Duffus. Chronic health conditions in Medicare beneficiaries 65 years old, and older with HIV infection. AIDS. 2016;30:2529-36. DOI: 10.1097/QAD.0000000000001215. [PMID:27478988]

[26] RA van Zoest, FW Wit, KW Kooij, M van der Valk, J Schouten, and NA Kootstra. Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure. Clin Infect Dis. 2016;63:205-13. DOI: 10.1093/cid/ciw285. [PMID:27143668]

[27] M Gelpi, S Afzal, J Lundgren, A Ronit, A Roen, and A Mocroft. Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study. Clin Infect Dis. 2018;67:579-86. DOI: 10.1093/cid/ciy146. [PMID:29471519]

[28] KH Mayer, S Loo, PM Crawford, HM Crane, M Leo, and P DenOuden. Excess Clinical Comorbidity Among HIV-Infected Patients Accessing Primary Care in US Community Health Centers. Public Health Rep. 2018;133:109-18. DOI: 10.1177/0033354917748670. [PMID:29262289]

[29] SC Mathabire Rücker, A Tayea, J Bitilinyu-Bangoh, EH Bermúdez-Aza, L Salumu, and IA Quiles. High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi. AIDS. 2018;32:253-60. DOI: 10.1097/QAD.0000000000001700. [PMID:29135581]

[30] J Manne-Goehler, MJ Siedner, L Montana, G Harling, P Geldsetzer, and J Rohr. Hypertension and diabetes control along the HIV care cascade in rural South Africa. J Int AIDS Soc. 2019;22:e25213. DOI: 10.1002/jia2.25213. [PMID:30916897]

[31] HY Yang, MR Beymer, and SC Suen. Chronic Disease Onset Among People Living with HIV and AIDS in a Large Private Insurance Claims Dataset. Sci Rep. 2019;9:18514 DOI: 10.1038/s41598-019-54969-3. [PMID:31811207]

[32] E Russell, A Albert, H Côté, A Hsieh, A Nesbitt, and AR Campbell. Rate of dyslipidemia higher among women living with HIV: A comparison of metabolic and cardiovascular health in a cohort to study aging in HIV. HIV Med. 2020;21:418-28. DOI: 10.1111/hiv.12843. [PMID:32168418]

[33] G Touloumi, N Kalpourtzi, V Papastamopoulos, V Paparizos, G Adamis, and A Antoniadou. Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece. PLoS One. 2020;15:e0230730. DOI: 10.1371/journal.pone.0230730. [PMID:32226048]

[34] X Xu, H Lin, X Chen, B Zhu, W Shen, and C Ning. Differences in hypertension and prehypertension among people living with and without HIV in China: role of HIV infection and antiretroviral therapy. HIV Med. 2021;22:409-17. DOI: 10.1111/hiv.13040. [PMID:33421323]

[35] R Enriquez, R Ssekubugu, A Ndyanabo, G Marrone, B Gigante, and LW Chang. Prevalence of cardiovascular risk factors by HIV status in a population-based cohort in South Central Uganda: a cross-sectional survey. J Int AIDS Soc. 2022;25:e25901. DOI: 10.1002/jia2.25901. [PMID:35419976]

[36] TE Gooden, M Gardner, J Wang, K Jolly, DA Lane, and LA Benjamin. Incidence of Cardiometabolic Diseases in People With and Without Human Immunodeficiency Virus in `the United Kingdom: A Population-Based Matched Cohort Study. J Infect Dis. 2022;225:1348-56. DOI: 10.1093/infdis/jiab420. [PMID:34417792]

[37] BI Jones, A Freedman, MJ Thomas, C Villalba-Mendez, L Sathia, and D Flanagan. Comorbid diseases and conditions in people with HIV in the UK. Curr Med Res Opin. 2022;38:277-85. DOI: 10.1080/03007995.2021.2003671. [PMID:34761727]

[38] JN Mogaka, M Sharma, T Temu, S Masyuko, J Kinuthia, and A Osoti. Prevalence and factors associated with hypertension among adults with and without HIV in Western Kenya. PLoS One. 2022;17:e0262400. DOI: 10.1371/journal.pone.0262400. [PMID:35007291]

[39] DR Morales, D Moreno-Martos, N Matin, and P McGettigan. Health conditions in adults with HIV compared with the general population: A population-based cross-sectional analysis. EClinicalMedicine. 2022;47:101392. DOI: 10.1016/j.eclinm.2022.101392. [PMID:35497059]

[40] SJ Masyuko, ST Page, J Kinuthia, AO Osoti, SJ Polyak, and FC Otieno. Metabolic syndrome and 10-year cardiovascular risk among HIV-positive and HIV-negative adults: A cross-sectional study. Medicine (Baltimore). 2020;99:e20845. DOI: 10.1097/MD.0000000000020845. [PMID:32629671]

[41] H Tilahun, SJ Masyuko, JN Mogaka, T Temu, J Kinuthia, and AO Osoti. Prevalence and correlates of dyslipidemia in HIV positive and negative adults in Western Kenya: A cross-sectional study. Medicine (Baltimore). 2021;100:e24800. DOI: 10.1097/MD.0000000000024800. [PMID:33725834]

[42] D Chow, R Young, N Valcour, RA Kronmal, CJ Lum, and NI Parikh. HIV and coronary artery calcium score: comparison of the Hawaii Aging with HIV Cardiovascular Study and Multi-Ethnic Study of Atherosclerosis (MESA) cohorts. HIV Clin Trials. 2015;16:130-8. DOI: 10.1179/1528433614Z.0000000016. [PMID:26038953]

[43] LA Kingsley, J Deal, L Jacobson, M Budoff, M Witt, and F Palella. Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men. AIDS. 2015;29:2427-34. DOI: 10.1097/QAD.0000000000000847. [PMID:26558542]

[44] PE Miller, SA Haberlen, T Metkus, P Rezaeian, F Palella, and LA Kingsley. HIV and coronary arterial remodeling from the Multicenter AIDS Cohort Study (MACS). Atherosclerosis. 2015;241:716-22. DOI: 10.1016/j.atherosclerosis.2015.06.022. [PMID:26132282]

[45] RS Rosenson, D Hubbard, KL Monda, SR Reading, L Chen, and PJ Dluzniewski. Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era. J Am Heart Assoc. 2020;9:e013744. DOI: 10.1161/JAHA.119.013744. [PMID:31880980]

[46] PE Tarr, B Ledergerber, A Calmy, T Doco-Lecompte, IC Schoepf, and A Marzel. Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography. Open Forum Infect Dis. 2020;7:ofaa438. DOI: 10.1093/ofid/ofaa438. [PMID:33134415]

[47] OA Badejo, CC Chang, KA So-Armah, RP Tracy, JV Baker, and D Rimland. CD8+ T-cells count in acute myocardial infarction in HIV disease in a predominantly male cohort. BioMed Res Int. 2015;2015:246870. DOI: 10.1155/2015/246870. [PMID:25688354]

[48] DB Klein, WA Leyden, LF Xu, CR Chao, MA Horberg, and WJ Towner. Declining Relative Risk for Myocardial Infarction Among HIV-Positive Compared With HIV-Negative Individuals With Access to Care. Clin Infect Dis. 2015;60:1278-80. DOI: 10.1093/cid/civ014. [PMID:25595743]

[49] AL Paisible, CCH Chang, KA So-Armah, AA Butt, DA Leaf, and M Budoff. HIV Infection, Cardiovascular Disease Risk Factor Profile, and Risk for Acute Myocardial Infarction. J Acquir Immune Defic Syndr. 2015;68:209-16. DOI: 10.1097/QAI.0000000000000419. [PMID:25588033]

[50] LD Rasmussen, M Helleberg, MT May, S Afzal, G Kronborg, and CS Larsen. Myocardial Infarction Among Danish HIV-Infected Individuals: Population-Attributable Fractions Associated With Smoking. Clin Infect Dis. 2015;60:1415-23. DOI: 10.1093/cid/civ013. [PMID:25595744]

[51] DR Drozd, MM Kitahata, KN Althoff, J Zhang, SJ Gange, and S Napravnik. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr. 2017;75:568-76. DOI: 10.1097/QAI.0000000000001450. [PMID:28520615]

[52] A Alonso, AE Barnes, JL Guest, A Shah, IY Shao, and V Marconi. HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database. J Am Heart Assoc. 2019;8:e012241. DOI: 10.1161/JAHA.119.012241. [PMID:31266386]

[53] M Masiá, S Padilla, JA Garcia, J García-Abellán, M Fernández, and I Bernardino. Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004-2015. PLoS One. 2019;14:e0215507. DOI: 10.1371/journal.pone.0215507. [PMID:31026289]

[54] E Nou, J Lo, C Hadigan, and SK Grinspoon. Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol. 2016;4:598-610. DOI: 10.1016/S2213-8587(15)00388-5. [PMID:26873066]

[55] J Martínez-Sanz, S Serrano-Villar, A Muriel, LJ García Fraile, E Orviz, and Á Mena de Cea. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study. Clin Infect Dis. 2023;76:e652-60. DOI: 10.1093/cid/ciac621. [PMID:35903910]

[56] C Chartrand-Lefebvre, M Durand, and C Tremblay. HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;161:923 DOI: 10.7326/L14-5033. [PMID:25506860]

[57] PE Tarr, B Ledergerber, A Calmy, T Doco-Lecompte, A Marzel, and R Weber. Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. Eur Heart J. 2018;39:2147-54. DOI: 10.1093/eurheartj/ehy163. [PMID:29590332]

[58] MS Freiberg, CC Chang, LH Kuller, M Skanderson, E Lowy, and KL Kraemer. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614-22. DOI: 10.1001/jamainternmed.2013.3728. [PMID:23459863]

[59] B Enkhmaa, E Anuurad, W Zhang, CS Li, R Kaplan, and J Lazar. Lipoprotein(a) and HIV: Allele-Specific Apolipoprotein(a) Levels Predict Carotid Intima-Media Thickness in HIV-Infected Young Women in the Women’s Interagency HIV Study. Arterioscler Thromb Vasc Biol. 2017;37:997-1004. DOI: 10.1161/ATVBAHA.117.309137. [PMID:28336560]

[60] D Kwarisiima, L Balzer, D Heller, P Kotwani, G Chamie, and T Clark. Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda. PLoS One. 2016;11:e0156309. DOI: 10.1371/journal.pone.0156309. [PMID:27232186]

[61] G Guaraldi, G Orlando, S Zona, M Menozzi, F Carli, and E Garlassi. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120-6. DOI: 10.1093/cid/cir627. [PMID:21998278]

[62] J Schouten, FW Wit, IG Stolte, NA Kootstra, M van der Valk, and SE Geerlings. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787-97. DOI: 10.1093/cid/ciu701. [PMID:25182245]

[63] L Partridge, J Deelen, and PE Slagboom. Facing up to the global challenges of ageing. Nature. 2018;561:45-56. DOI: 10.1038/s41586-018-0457-8. [PMID:30185958]

[64] K So-Armah, LA Benjamin, GS Bloomfield, MJ Feinstein, P Hsue, and B Njuguna. HIV and cardiovascular disease. Lancet HIV. 2020;7:e279-93. DOI: 10.1016/S2352-3018(20)30036-9. [PMID:32243826]

[65] L Stone, SE Looby, and MV Zanni. Cardiovascular disease risk among women living with HIV in North America and Europe. Curr Opin HIV AIDS. 2017;12:585-93. DOI: 10.1097/COH.0000000000000413. [PMID:28832367]

[66] C Magnussen, FM Ojeda, DP Leong, J Alegre-Diaz, P Amouyel, and L Aviles-Santa. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023;389:1273-85. DOI: 10.1056/NEJMoa2206916. [PMID:37632466]

[67] SW Worm, C Sabin, R Weber, P Reiss, W El-Sadr, and F Dabis. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-30. DOI: 10.1086/649897. [PMID:20039804]

[68] P Willeit, L Tschiderer, E Allara, K Reuber, L Seekircher, and L Gao. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation. 2020;142:621-42. DOI: 10.1161/CIRCULATIONAHA.120.046361. [PMID:32546049]

[69] NG Sandler, H Wand, A Roque, M Law, MC Nason, and DE Nixon. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780-90. DOI: 10.1093/infdis/jiq118. [PMID:21252259]

[70] RA McKibben, JB Margolick, S Grinspoon, X Li, FJ Palella, and LA Kingsley. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis. 2015;211:1219-28. DOI: 10.1093/infdis/jiu594. [PMID:25362192]

[71] A Kearns, J Gordon, TH Burdo, and X Qin. HIV-1-Associated Atherosclerosis: Unraveling the Missing Link. J Am Coll Cardiol. 2017;69:3084-98. DOI: 10.1016/j.jacc.2017.05.012. [PMID:28641798]

[72] DM Xu, Q Li, JX Yi, XJ Cai, L Xie, and W Fang. Investigation of Lymphocyte Subsets in Peripheral Blood of Patients with Dyslipidemia. Int J Gen Med. 2021;14:5573-9. DOI: 10.2147/IJGM.S326628. [PMID:34548808]

[73] EN Anyabolu. Dyslipidemia in people living with HIV-AIDS in a tertiary hospital in South-East Nigeria. Pan Afr Med J. 2017;28:204 DOI: 10.11604/pamj.2017.28.204.13505. [PMID:29610642]

[74] S Grinspoon and A Carr. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. [PMID:15635112]

[75] AE Moran, MH Forouzanfar, GA Roth, GA Mensah, M Ezzati, and A Flaxman. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014;129:1493-501. DOI: 10.1161/CIRCULATIONAHA.113.004046. [PMID:24573351]

Correspondence to:
Xiaojie Huang
Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University
No.8 Xitoutiao, Youanmenwai, Feng Tai District
PR China
[email protected]